Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma
- PMID: 35568521
- DOI: 10.1016/j.jtcvs.2022.02.055
Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma
Abstract
Objective: Discrete anterior mediastinal masses most often represent thymoma or lymphoma. Lymphoma treatment is nonsurgical and requires biopsy. Noninvasive thymoma is ideally resected without biopsy, which may potentiate pleural metastases. This study sought to determine if clinical criteria or positron emission tomography/computed tomography could accurately differentiate the 2, guiding a direct surgery versus biopsy decision.
Methods: A total of 48 subjects with resectable thymoma and 29 subjects with anterior mediastinal lymphoma treated from 2006 to 2019 were retrospectively examined. All had pretreatment positron emission tomography/computed tomography and appeared resectable (solitary, without clear invasion or metastasis). Reliability of clinical criteria (age and B symptoms) and positron emission tomography/computed tomography maximum standardized uptake value were assessed in differentiating thymoma and lymphoma using Wilcoxon rank-sum test, chi-square test, and logistic regression. Receiver operating characteristic analysis identified the maximum standardized uptake value threshold most associated with thymoma.
Results: There was no association between tumor type and age group (P = .183) between those with thymoma versus anterior mediastinal lymphoma. Patients with thymoma were less likely to report B symptoms (P < .001). The median maximum standardized uptake value of thymoma and lymphoma differed dramatically: 4.35 versus 18.00 (P < .001). Maximum standardized uptake value was independently associated with tumor type on multivariable regression. On receiver operating characteristic analysis, lower maximum standardized uptake value was associated with thymoma. Maximum standardized uptake value less than 12.85 was associated with thymoma with 100.00% sensitivity and 88.89% positive predictive value. Maximum standardized uptake value less than 7.50 demonstrated 100.00% positive predictive value for thymoma.
Conclusions: Positron emission tomography/computed tomography maximum standardized uptake value of resectable anterior mediastinal masses may help guide a direct surgery versus biopsy decision. Tumors with maximum standardized uptake value less than 7.50 are likely thymoma and thus perhaps appropriately resected without biopsy. Tumors with maximum standardized uptake value greater than 7.50 should be biopsied to rule out lymphoma. Lymphoma is likely with maximum standardized uptake value greater than 12.85.
Keywords: PET/CT; SUVmax; anterior mediastinal masses; lymphoma; thymoma.
Copyright © 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commentary: Lest we biopsy: Positron emission tomography-computed tomography as a tool to achieve a "greater good" in the diagnosis and management of the resectable anterior mediastinal mass.J Thorac Cardiovasc Surg. 2023 Jan;165(1):382-383. doi: 10.1016/j.jtcvs.2022.02.057. Epub 2022 Apr 6. J Thorac Cardiovasc Surg. 2023. PMID: 35525804 No abstract available.
Similar articles
-
Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses.Eur J Cardiothorac Surg. 2009 Sep;36(3):475-9. doi: 10.1016/j.ejcts.2009.03.055. Epub 2009 Jun 5. Eur J Cardiothorac Surg. 2009. PMID: 19501523
-
Positron emission tomography/computed tomography as a clinical diagnostic tool for anterior mediastinal tumors.Surg Today. 2019 Feb;49(2):143-149. doi: 10.1007/s00595-018-1712-1. Epub 2018 Sep 10. Surg Today. 2019. PMID: 30198048
-
A diagnostic cohort study on the accuracy of 18-fluorodeoxyglucose (18FDG) positron emission tomography (PET)-CT for evaluation of malignancy in anterior mediastinal lesions: the DECiMaL study.BMJ Open. 2018 Feb 6;8(2):e019471. doi: 10.1136/bmjopen-2017-019471. BMJ Open. 2018. PMID: 29437755 Free PMC article.
-
[(18)F]2-fluoro-2-deoxy-D-glucose PET/CT in mediastinal masses.Cancer Imaging. 2010 Oct 4;10 Spec no A(1A):S156-60. doi: 10.1102/1470-7330.2010.9026. Cancer Imaging. 2010. PMID: 20880785 Free PMC article. Review.
-
[Standard report terms for chest computed tomography reports of anterior mediastinal masses suspicious for thymoma].Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):82-9. doi: 10.3779/j.issn.1009-3419.2014.02.04. Zhongguo Fei Ai Za Zhi. 2014. PMID: 24581157 Free PMC article. Review. Chinese. No abstract available.
Cited by
-
Practical methods to differentiate thymic malignancies by positron-emission tomography and tumor markers.Surg Today. 2024 Aug;54(8):899-906. doi: 10.1007/s00595-024-02801-5. Epub 2024 Feb 27. Surg Today. 2024. PMID: 38411770
-
CT radiomics and human-machine hybrid system for differentiating mediastinal lymphomas from thymic epithelial tumors.Cancer Imaging. 2024 Nov 28;24(1):163. doi: 10.1186/s40644-024-00808-2. Cancer Imaging. 2024. PMID: 39609913 Free PMC article.
-
A diagnostic model based on 18F-FDG PET/CT parameters in improving the differential diagnosis of invasive thymic epithelial tumors and anterior mediastinal lymphomas.BMC Med Imaging. 2024 Jan 8;24(1):14. doi: 10.1186/s12880-023-01185-1. BMC Med Imaging. 2024. PMID: 38191331 Free PMC article.
-
The role of positron emission tomography in mediastinal mass.Mediastinum. 2025 Mar 6;9:8. doi: 10.21037/med-24-44. eCollection 2025. Mediastinum. 2025. PMID: 40224339 Free PMC article. Review.
-
Practical value of fluorodeoxyglucose positron emission tomography in treatment strategies for thymic epithelial tumors: implications for more specific use in routine clinical practice.Mediastinum. 2025 Mar 6;9:7. doi: 10.21037/med-24-46. eCollection 2025. Mediastinum. 2025. PMID: 40224337 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical